Incyte | INCY - Sales Revenues

Stock Price
108.39
Daily Change
5.63 5.48%
Monthly
-1.97%
Yearly
46.22%
Q1 Forecast
96.99

Incyte reported $1.37B in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Exelixis USD 597.8M 29.5M Sep/2025
Gilead Sciences USD 7.8B 700M Sep/2025
Incyte USD 1.37B 310M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
MacroGenics USD 72.84M 50.6M Sep/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 1.02B 878M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
Novartis USD 13.91B 144M Sep/2025
Novartis USD 14.36B 478M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025